Acorda Therapeutics, Inc.

OTCPK:ACOR.Q Stock Report

Market Cap: US$37.4k

Acorda Therapeutics Past Earnings Performance

Past criteria checks 0/6

Acorda Therapeutics has been growing earnings at an average annual rate of 5.3%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been declining at an average rate of 22% per year.

Key information

5.3%

Earnings growth rate

29.1%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate-22.0%
Return on equityn/a
Net Margin-227.8%
Last Earnings Update31 Mar 2024

Recent past performance updates

Recent updates

Health Check: How Prudently Does Acorda Therapeutics (NASDAQ:ACOR) Use Debt?

Feb 21
Health Check: How Prudently Does Acorda Therapeutics (NASDAQ:ACOR) Use Debt?

Acorda Therapeutics, Inc. (NASDAQ:ACOR) Surges 53% Yet Its Low P/S Is No Reason For Excitement

Dec 18
Acorda Therapeutics, Inc. (NASDAQ:ACOR) Surges 53% Yet Its Low P/S Is No Reason For Excitement

Is Acorda Therapeutics (NASDAQ:ACOR) Using Debt Sensibly?

Jun 05
Is Acorda Therapeutics (NASDAQ:ACOR) Using Debt Sensibly?

Acorda wins $16.5M in Ampyra arbitration case with Alkermes

Oct 17

Acorda stock rise 11% as proposal to increase shares withdrawn; reverse split still on vote

Oct 10

Acorda inks license deal with Asieris for pre-clinical drug

Aug 29

Acorda Therapeutics announces resignation of COO

Aug 19

Acorda Therapeutics: Managing The Transition

Oct 04

Acorda Therapeutics Continues To Maneuver For A Turnaround

Jul 24

CureVac downgraded following COVID vaccine data, Regeneron COVID cocktail a boon, and more in analyst action

Jun 17

Shareholders May Be More Conservative With Acorda Therapeutics, Inc.'s (NASDAQ:ACOR) CEO Compensation For Now

May 26
Shareholders May Be More Conservative With Acorda Therapeutics, Inc.'s (NASDAQ:ACOR) CEO Compensation For Now

Acorda Therapeutics, Inc. 2021 Q1 - Results - Earnings Call Presentation

May 07

Acorda Therapeutics, Inc.'s (NASDAQ:ACOR) Sole Analyst Just Made A Huge Upgrade To Their Forecasts

Mar 09
Acorda Therapeutics, Inc.'s (NASDAQ:ACOR) Sole Analyst Just Made A Huge Upgrade To Their Forecasts

Revenue & Expenses Breakdown

How Acorda Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

OTCPK:ACOR.Q Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 24116-263960
31 Dec 23118-253900
30 Sep 23111-16930
30 Jun 23117-21930
31 Mar 23118-581020
31 Dec 22119-661060
30 Sep 22124-1061030
30 Jun 22122-1191100
31 Mar 22123-951120
31 Dec 21129-1041190
30 Sep 21130-1661290
30 Jun 21152-1321390
31 Mar 21154-1271450
31 Dec 20153-1001530
30 Sep 20165491580
30 Jun 20160-222167-35
31 Mar 20176-232178-16
31 Dec 19192-2731900
30 Sep 19211-32918826
30 Jun 19306-7918384
31 Mar 19409-617791
31 Dec 1847134172105
30 Sep 18591-147172109
30 Jun 18589-158169119
31 Mar 18575-213174145
31 Dec 17588-223180161
30 Sep 17541-55184185
30 Jun 17535-43198206
31 Mar 17523-53211205
31 Dec 16520-35218203
30 Sep 16510-22229194
30 Jun 16522-6226182
31 Mar 1650914216163
31 Dec 1549311205149
30 Sep 154802202131
30 Jun 1543710199104
31 Mar 154211419690
31 Dec 144011820273
30 Sep 143762419162
30 Jun 143551918659
31 Mar 143451818356
31 Dec 133361618554
30 Sep 1332514318358

Quality Earnings: ACOR.Q is currently unprofitable.

Growing Profit Margin: ACOR.Q is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: ACOR.Q is unprofitable, but has reduced losses over the past 5 years at a rate of 5.3% per year.

Accelerating Growth: Unable to compare ACOR.Q's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ACOR.Q is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.5%).


Return on Equity

High ROE: ACOR.Q's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies